

Third Quarter 2025 Earnings

EARNINGS PRESENTATION

October 29, 2025

Forward Looking Statements, Non-GAAP Financial Measures, & Basis of Presentation

FORWARD-LOOKING STATEMENTS

Statements in this presentation that are not strictly historical, including statements regarding anticipated financial results, global and regional economic conditions, industry trends, geopolitical events, future acquisitions, impact of trade and spending policies, the ability to execute the planned strategies, interest rate and current exchange rate impact, future prospects, shareholder value, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” “target”, or “will” or other words of similar meaning, are “forward-looking statements” within the meaning of the United States federal securities laws. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: deterioration of or instability in the economy, the markets we serve, international trade policies and deteriorating trade relations with other countries, including imposition of tariffs and retaliatory tariffs between United States and China and other countries, responsive economic nationalism, trade restrictions, and enhanced regulation, impact of any prolonged government shutdown, the financial markets, geopolitical conditions and conflicts, security breaches or other disruptions of our information technology systems, supply chain constraints, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, contractions or lower growth rates and cyclicalities of markets we serve, competition, changes in industry standards and governmental regulations, our ability to recruit and retain key employees, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, geopolitical, including war and sanctions, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, adverse effects of restructuring activities, our plans to separate into two independent, publicly-traded companies, risk related to tax treatment of our prior separations, impact of our indemnification obligation to Ralliant and Vontier, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters and climate change. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Reports on Form 10-Q for the subsequent quarters. These forward-looking statements speak only as of the date of this presentation, and Fortive does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

NON-GAAP FINANCIAL MEASURES

This presentation contains references to financial measures not presented in accordance with generally accepted accounting principles (“GAAP”). We have not reconciled forward-looking targets or outlook regarding non-GAAP measures because any corresponding GAAP measures and the reconciliations thereto would require us to make estimates or assumptions with precision about acquisitions, currency transactions, capital and other expenditures and similar adjustments during the relevant period. Information required by Regulation G with respect to historical non-GAAP financial measures are set forth in the appendix to this presentation and the “Investors” section of our website, www.fortive.com, under the heading “Financial Results”.

PRECISION TECHNOLOGIES SEPARATION

On June 28, 2025, the Company completed the separation (the “Separation”) of its former Precision Technologies segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation (“Ralliant”), the entity incorporated to hold the PT businesses. The accounting requirements for reporting Ralliant as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying financial information for all periods presented reflect this business as a discontinued operation. Unless otherwise indicated, all references in this report refer to continuing operations.

All growth or period changes refer to year-over-year comparisons unless otherwise stated. Forward looking financial information not otherwise presented as a range reflect assumptions underlying the midpoint of our forward-looking targets.

Key Messages



1

Strong execution in our first quarter as new Fortive with solid performance across all key financial metrics

2

Raising FY adjusted EPS guidance to \$2.63 to \$2.67, reflecting strong Q3 Adj. EPS performance

3

\$1B of share repurchases in Q3 underscores our commitment to disciplined capital allocation approach, with best relative equity returns as our North Star

4

Diligently executing Fortive *Accelerated* strategy, continued confidence in financial framework and value creation opportunity


Fortive *Accelerated*

Faster, Profitable Organic Growth Powered by FBS Amplified



Innovation Acceleration

- New product velocity beginning to accelerate as a result of renewed focus on customer-centric innovation. Q3 notable product launches included:
 - ServiceChannel SaaS R2 product release, featuring AI-powered work order insights, reduces multi-visit inefficiencies and streamlines payment solutions
 - Fluke GFL 1500 Solar Ground Fault Locator marks further play into high-growth solar vertical and increases customer productivity
- Launched new innovation studio and customer experience centers for collaboration and innovation to deepen customer relationships



Commercial Acceleration

- Reorienting commercial strategies toward high-growth opportunities is showing signs of early success, and we are planting seeds for further acceleration:
 - Recent commercial initiatives aimed at high-growth verticals beginning to have a positive impact on performance in North America across the portfolio
 - Increased efforts in South Asia with an enhanced regional presence driving significant acceleration across both segments



Recurring Customer Value

- Strengthening focus on recurring revenue growth opportunities to enhance durability:
 - Fluke annual recurring revenue (ARR) from software and services continued pace of double-digit growth driven by software enhancements and increasing demand
 - Fortive recurring revenue growth outpacing consolidated growth

Capital Allocation

- Clear priorities to invest in organic growth, pursue accretive bolt-on M&A, return capital through share repurchases, and maintain a modest dividend
- Executed \$1B of share repurchases in Q3, retiring ~21M shares at an average ~\$48 per share
- Revamped our M&A funnel and process to reflect our different M&A strategy going forward – focused on accretive, smaller bolt-on M&A

Fortive Results

Q3 2025, Continuing Operations

	Q3 2025
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$1,027M +2.3% +1.9%
Adj. Gross Profit <i>Adj. Gross Margin</i> <i>Adj. Gross Profit Growth (YoY)</i>	\$651M 63.3% +1.4%
Adj. EBITDA <i>Adj. EBITDA Margin</i> <i>Adj. EBITDA Growth (YoY)</i>	\$309M 30.1% +10.4%
Adj. EPS <i>Adj. EPS Growth (YoY)</i>	\$0.68 +15.3%
Free Cash Flow TTM Free Cash Flow <i>TTM FCF Conversion on Adj. Net Income</i> <i>TTM FCF Growth</i>	\$266M \$922M 103% +5.5%

COMMENTARY

- Core growth of ~2% reflects growth at both segments amidst dynamic market conditions; sequential improvement in North America, partially offset by macro weakness in Europe
- Adjusted Gross Profit up slightly year over year; Adj. Gross Margin down slightly on tariff-related cost pressures offset by pricing and supply chain countermeasures
- Adj. EBITDA grew +10% year over year, reflecting FBS-driven cost management and corporate cost optimization
- Adj. EPS grew +15% year over year, driven by Adj. EBITDA growth, lower interest expense, and favorable impact of share repurchases
- Trailing Twelve Month (TTM) Free Cash Flow Conversion on Adj. Net Income of >100%

Intelligent Operating Solutions

Q3 2025, Continuing Operations

	Q3 2025
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$699M +2.6% +2.2%
Adj. Gross Profit <i>Adj. Gross Margin</i> <i>Adj. Gross Profit Growth (YoY)</i>	\$459M 65.7% +1.1%
Adj. EBITDA <i>Adj. EBITDA Margin</i> <i>Adj. EBITDA Growth (YoY)</i>	\$242M 34.6% +6.7%

COMMENTARY

- Revenue growth driven by strength in FAL software, professional instrumentation, and gas detection, partially offset by continued government pressure in construction procurement software
- Adj. Gross Profit up modestly from last year, driven by revenue growth, partially offset by tariff cost pressures
- Adj. EBITDA grew ~7%, driven by modest Adj. Gross Profit growth and disciplined cost management

Advanced Healthcare Solutions

Q3 2025, Continuing Operations

	Q3 2025
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$328M +1.9% +1.1%
Adj. Gross Profit <i>Adj. Gross Margin</i> <i>Adj. Gross Profit Growth (YoY)</i>	\$192M 58.4% +2.1%
Adj. EBITDA <i>Adj. EBITDA Margin</i> <i>Adj. EBITDA Growth (YoY)</i>	\$92M 28.1% +6.6%

COMMENTARY

- Revenue growth driven by continued strength in resilient, SaaS-based healthcare software
- Sequential improvement in healthcare equipment demand in North America, despite continued headwinds from healthcare policy and funding changes
- Adj. Gross Profit growth in line with revenue growth; Adj. Gross Margins slightly up
- Adj. EBITDA grew ~7%, driven by Adj. Gross Profit growth and lower operating costs

Balance Sheet & Capital Allocation

Q3 2025

Balance Sheet	As of September 26, 2025
Cash and equivalents	\$0.4B
Gross debt	\$3.3B
Net debt	\$2.9B
Q3 2025 TTM Adj. EBITDA	\$1.2B
Gross Debt / Adj. EBITDA	~2.7x
Net Debt / Adj. EBITDA	~2.4x
Cash Flow, Continuing Operations	TTM as of Q3 2025
Operating Cash Flow	\$1,019M
Capital Expenditures	\$97M
Free Cash Flow	\$922M
Free Cash Flow Growth (YoY)	+6%

COMMENTARY

- \$1B capital deployed towards share repurchase in the quarter; repurchased ~21M shares at an average price of ~\$48 per share
- Ample capacity and flexibility to execute our capital deployment priorities, always with a disciplined focus on allocating capital based on relative risk-adjusted equity returns

Guidance

As of Q3 2025, Continuing Operations

Adj. EPS | FY 2025

\$2.63 - \$2.67

- Guidance raised by \$0.10 at the midpoint, reflecting Q3 outperformance
- Assumes current demand environment continues through the rest of 2025
- Includes net impact of current or known future tariffs expected through the end of the year, including China¹



Fortive *Accelerated*

Innovating essential
technologies to keep our
world **safe** and **productive**



Supplemental Reconciliation Data

CORE REVENUE GROWTH

Components of Revenue Growth	Three Months Ended					
	September 26, 2025			September 27, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Total revenue growth (GAAP)	2.6 %	1.9 %	2.3 %	2.8 %	8.3 %	4.5 %
Excluding impact of:						
Acquisitions and divestitures	0.5 %	— %	0.3 %	(0.8)%	— %	(0.6)%
Currency exchange rates	(0.9)%	(0.8)%	(0.7)%	(0.3)%	0.9 %	0.1 %
Core revenue growth (Non-GAAP)	2.2 %	1.1 %	1.9 %	1.7 %	9.2 %	4.0 %

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN

\$ in millions	Three Months Ended September 26, 2025			Three Months Ended September 27, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 698.8	\$ 328.3	\$ 1,027.1	\$ 681.3	\$ 322.4	\$ 1,003.7
Gross Profit (GAAP)	\$ 457.5	\$ 191.7	\$ 649.2	\$ 453.7	\$ 187.8	\$ 641.5
Discrete Restructuring Charges	1.4	—	1.4	—	—	—
Adjusted Gross Profit (Non-GAAP)	\$ 458.9	\$ 191.7	\$ 650.6	\$ 453.7	\$ 187.8	\$ 641.5
Gross Profit Margin (GAAP)	65.5 %	58.4 %	63.2 %	66.6 %	58.3 %	63.9 %
Adjusted Gross Profit Margin (Non-GAAP)	65.7 %	58.4 %	63.3 %	66.6 %	58.3 %	63.9 %

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN FROM CONTINUING OPERATIONS

\$ in millions	Three Months Ended	
	September 26, 2025	September 27, 2024
Revenue (GAAP)	\$ 1,027.1	\$ 1,003.7
Net Earnings from Continuing Operations (GAAP)	\$ 117.0	\$ 111.5
Interest expense, net	25.4	37.1
Income taxes	18.0	(2.4)
Depreciation	17.6	15.8
Amortization	91.5	92.0
EBITDA from Continuing Operations (Non-GAAP)	269.5	254.0
Pretax acquisition, divestiture, and Separation related items ^(a)	38.3	0.1
Pretax discrete restructuring charges	2.1	—
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	(0.5)	—
Pretax losses from equity investments	—	26.2
Adjusted EBITDA from Continuing Operations (Non-GAAP)	\$ 309.4	\$ 280.3
Net Earnings Margin from Continuing Operations (GAAP)	11.4 %	11.1 %
Adjusted EBITDA Margin from Continuing Operations (Non-GAAP)	30.1 %	27.9 %

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted EBITDA may not equal due to rounding.

FORTIVE CONTINUING OPERATIONS: OPERATING PROFIT & OPERATING PROFIT MARGIN TO ADJUSTED EBITDA AND ADJUSTED MARGIN BRIDGE

\$ in millions	Three Months Ended	
	September 26, 2025	September 27, 2024
Revenue (GAAP)	\$ 1,027.1	\$ 1,003.7
Operating Profit (GAAP)	\$ 159.6	\$ 172.0
Amortization of acquisition-related intangible assets and non-cash impairments	91.5	92.0
Acquisition, divestiture, and separation related items ^(a)	38.3	0.1
Discrete restructuring charges	2.1	—
Adjusted Operating Profit (Non-GAAP)	\$ 291.5	\$ 264.1
Depreciation	17.6	15.8
Other	0.3	0.4
Adjusted EBITDA from Continuing Operations (Non-GAAP)	\$ 309.4	\$ 280.3
Operating Profit Margin (GAAP)	15.5 %	17.1 %
Adjusted Operating Profit Margin (Non-GAAP)	28.4 %	26.3 %
Adjusted EBITDA Margin from Continuing Operations (Non-GAAP)	30.1 %	27.9 %

^(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs and corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN

\$ in millions	Three Months Ended September 26, 2025				Three Months Ended September 27, 2024			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)	\$ 698.8	\$ 328.3	\$ —	\$ 1,027.1	\$ 681.3	\$ 322.4	\$ —	\$ 1,003.7
Operating Profit (GAAP)	\$ 180.7	\$ 42.5	\$ (63.6)	\$ 159.6	\$ 169.0	\$ 36.7	\$ (33.7)	\$ 172.0
Amortization of acquisition-related intangible assets	46.4	45.1	—	91.5	46.9	45.1	—	92.0
Acquisition, divestiture, and separation related items ^(a)	0.1	0.1	38.1	38.3	0.1	—	—	0.1
Discrete restructuring charges	2.0	0.1	—	2.1	—	—	—	—
Adjusted Operating Profit (Non-GAAP)	\$ 229.2	\$ 87.8	\$ (25.6)	\$ 291.5	\$ 216.0	\$ 81.8	\$ (33.7)	\$ 264.1
Depreciation	12.7	4.5			\$ 10.7	\$ 4.8		
Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) (Non-GAAP)	\$ 241.9	\$ 92.3			\$ 226.7	\$ 86.6		
Operating Profit Margin (GAAP)	25.9 %	12.9 %		15.5 %	24.8 %	11.4 %		17.1 %
Adjusted Operating Profit Margin (Non-GAAP)	32.8 %	26.7 %		28.4 %	31.7 %	25.4 %		26.3 %
Adjusted EBITDA Margin (Non-GAAP)	34.6 %	28.1 %			33.3 %	26.9 %		

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

ADJUSTED NET EARNINGS AND ADJUSTED DILUTED NET EPS FROM CONTINUING OPERATIONS

\$ in millions, except per share amounts

	Three Months Ended			
	September 26, 2025		September 27, 2024	
		Per share value		Per share value
Net Earnings and Net Earnings Per Share from Continuing Operations (GAAP)	\$	117.0	\$	0.35
Pretax amortization of acquisition related intangible assets		91.5		0.27
Pretax acquisition, divestiture, and separation related items ^(a)		38.3		0.11
Pretax discrete restructuring charges		2.1		0.01
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt		(0.5)		—
Pretax losses from equity investments		—		—
Tax effect of the adjustments reflected above ^(b)		(20.1)		26.2
Adjusted Net Earnings and Adjusted Net Earnings Per Share from Continuing Operations (Non-GAAP)	\$	228.3	\$	0.68
Average Common Diluted Stock Outstanding (shares in millions)		333.4		352.3

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

(b) The loss from divestiture in 2024 had no tax impact. The tax effect of the adjustments includes all other line items above.

The sum of the components of adjusted diluted net earnings per share may not equal due to rounding.

FREE CASH FLOW FROM CONTINUING OPERATIONS - TRAILING TWELVE MONTHS (in millions)

	Three Months Ended				Trailing Twelve Months
	September 26, 2025	June 27, 2025	March 28, 2025	December 31, 2024	
Operating Cash Flows (GAAP)	\$ 294.7	\$ 205.0	\$ 191.8	\$ 327.7	\$ 1,019.2
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(28.6)	(25.0)	(21.1)	(22.6)	(97.3)
Free Cash Flow (Non-GAAP)	\$ 266.1	\$ 180.0	\$ 170.7	\$ 305.1	\$ 921.9
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 228.3	\$ 197.8	\$ 191.1	\$ 279.8	\$ 897.0
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	116.6 %	91.0 %	89.3 %	109.0 %	102.8 %

	Three Months Ended				Trailing Twelve Months
	September 27, 2024	June 28, 2024	March 29, 2024	December 31, 2023	
Operating Cash Flows (GAAP)	\$ 304.7	\$ 217.5	\$ 178.6	\$ 259.8	\$ 960.6
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(21.6)	(19.6)	(22.3)	(23.4)	(86.9)
Free Cash Flow (Non-GAAP)	\$ 283.1	\$ 197.9	\$ 156.3	\$ 236.4	\$ 873.7
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 207.4	\$ 198.6	\$ 164.7	\$ 220.3	\$ 791.0
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	136.5 %	99.6 %	94.9 %	107.3 %	110.5 %

DISAGGREGATION OF REVENUE - TOTAL FORTIVE

\$ in millions	Three Months Ended				Year Ended	Three Months Ended				Year Ended	Three Months Ended		
	March 31, 2023	June 30, 2023	September 29, 2023	December 31, 2023	December 31, 2023	March 29, 2024	June 28, 2024	September 27, 2024	December 31, 2024	December 31, 2024	March 28, 2025	June 27, 2025	September 26, 2025
Geographic:													
North America	\$ 542.6	\$ 580.6	\$ 568.4	\$ 600.9	\$ 2,292.5	\$ 562.1	\$ 605.6	\$ 601.7	\$ 647.4	\$ 2,416.8	\$ 595.0	\$ 607.6	\$ 624.7
Asia-Pacific	184.0	186.4	175.5	181.3	727.2	194.0	177.6	177.8	183.9	733.3	185.2	175.7	181.4
Europe, Middle East, and Africa	170.1	170.2	165.8	191.4	697.5	181.0	179.9	168.1	192.1	721.1	167.4	181.1	167.9
Latin America	40.3	46.8	50.9	58.7	196.7	47.1	57.1	56.1	49.4	209.7	45.5	52.0	53.1
Total	\$ 937.0	\$ 984.0	\$ 960.6	\$ 1,032.3	\$ 3,913.9	\$ 984.2	\$ 1,020.2	\$ 1,003.7	\$ 1,072.8	\$ 4,080.9	\$ 993.1	\$ 1,016.4	\$ 1,027.1
End Markets:													
Healthcare	\$ 282.6	\$ 305.3	\$ 296.3	\$ 326.7	\$ 1,210.9	\$ 294.2	\$ 317.7	\$ 315.5	\$ 337.3	\$ 1,264.7	\$ 296.2	\$ 313.4	\$ 322.2
Industrial & Manufacturing	280.0	283.6	277.1	298.4	1,139.1	298.7	290.4	282.7	300.8	1,172.6	298.3	288.7	287.9
Energy & Infrastructure	156.8	159.5	160.1	157.4	633.8	162.7	164.3	157.5	175.0	659.5	165.6	167.5	166.7
Government	71.3	86.9	82.9	89.7	330.8	79.8	91.0	93.0	93.1	356.9	82.4	91.6	88.0
Retail	66.7	65.9	69.7	74.4	276.7	66.1	71.0	75.3	78.8	291.2	71.8	75.0	82.7
Other	79.6	82.8	74.5	85.7	322.6	82.7	85.8	79.7	87.8	336.0	78.8	80.2	79.6
Total	\$ 937.0	\$ 984.0	\$ 960.6	\$ 1,032.3	\$ 3,913.9	\$ 984.2	\$ 1,020.2	\$ 1,003.7	\$ 1,072.8	\$ 4,080.9	\$ 993.1	\$ 1,016.4	\$ 1,027.1

DISAGGREGATION OF REVENUE - SEGMENTS

\$ in millions

	Three Months Ended				Year Ended	Three Months Ended				Year Ended	Three Months Ended		
	March 31, 2023	June 30, 2023	September 29, 2023	December 31, 2023	December 31, 2023	March 29, 2024	June 28, 2024	September 27, 2024	December 31, 2024	December 31, 2024	March 28, 2025	June 27, 2025	September 26, 2025
Intelligent Operating Solutions													
Geographic:													
North America	\$ 377.5	\$ 400.4	\$ 401.2	\$ 413.4	\$ 1,592.5	\$ 390.7	\$ 421.3	\$ 412.8	\$ 449.7	\$ 1,674.5	\$ 415.0	\$ 421.5	\$ 433.2
Asia-Pacific	118.1	116.0	105.4	108.3	447.8	126.1	111.5	109.1	109.8	456.5	119.4	107.6	111.4
Europe, Middle East, and Africa	131.8	130.0	130.5	149.2	541.5	141.6	136.0	129.5	145.9	553.0	130.6	137.9	126.3
Latin America	22.2	24.4	25.8	30.3	102.7	26.0	27.8	29.9	25.5	109.2	25.9	29.9	27.9
Total	\$ 649.6	\$ 670.8	\$ 662.9	\$ 701.2	\$ 2,684.5	\$ 684.4	\$ 696.6	\$ 681.3	\$ 730.9	\$ 2,793.2	\$ 690.9	\$ 696.9	\$ 698.8
End Markets:													
Healthcare	\$ 11.1	\$ 11.7	\$ 11.0	\$ 14.7	\$ 48.5	\$ 11.5	\$ 11.4	\$ 10.6	\$ 14.0	\$ 47.5	\$ 10.7	\$ 10.9	\$ 10.8
Industrial & Manufacturing	275.7	279.1	273.2	293.7	1,121.7	294.1	285.8	278.5	295.9	1,154.3	293.8	284.2	284.3
Energy & Infrastructure	156.8	159.5	160.1	157.4	633.8	162.7	164.3	157.5	175.0	659.5	165.6	167.5	166.7
Government	62.9	78.2	74.6	78.4	294.1	70.7	81.7	82.9	83.0	318.3	73.5	82.5	78.1
Retail	66.7	65.9	69.7	74.4	276.7	66.1	71.0	75.3	78.8	291.2	71.8	75.0	82.7
Other	76.4	76.4	74.3	82.6	309.7	79.3	82.4	76.5	84.2	322.4	75.5	76.8	76.2
Total	\$ 649.6	\$ 670.8	\$ 662.9	\$ 701.2	\$ 2,684.5	\$ 684.4	\$ 696.6	\$ 681.3	\$ 730.9	\$ 2,793.2	\$ 690.9	\$ 696.9	\$ 698.8
Advanced Healthcare Solutions													
Geographic:													
North America	\$ 165.1	\$ 180.2	\$ 167.2	\$ 187.5	\$ 700.0	\$ 171.4	\$ 184.3	\$ 188.9	\$ 197.7	\$ 742.3	\$ 180.0	\$ 186.1	\$ 191.5
Asia-Pacific	65.9	70.4	70.1	73.0	279.4	67.9	66.1	68.7	74.1	276.8	65.8	68.1	70.0
Europe, Middle East, and Africa	38.3	40.2	35.3	42.2	156.0	39.4	43.9	38.6	46.2	168.1	36.8	43.2	41.6
Latin America	18.1	22.4	25.1	28.4	94.0	21.1	29.3	26.2	23.9	100.5	19.6	22.1	25.2
Total	\$ 287.4	\$ 313.2	\$ 297.7	\$ 331.1	\$ 1,229.4	\$ 299.8	\$ 323.6	\$ 322.4	\$ 341.9	\$ 1,287.7	\$ 302.2	\$ 319.5	\$ 328.3
End Markets:													
Healthcare	\$ 271.5	\$ 293.6	\$ 285.3	\$ 312.0	\$ 1,162.4	\$ 282.7	\$ 306.3	\$ 304.9	\$ 323.3	\$ 1,217.2	\$ 285.5	\$ 302.5	\$ 311.4
Industrial & Manufacturing	4.3	4.5	3.9	4.7	17.4	4.6	4.6	4.2	4.9	18.3	4.5	4.5	3.6
Government	8.4	8.7	8.3	11.3	36.7	9.1	9.3	10.1	10.1	38.6	8.9	9.1	9.9
Other	3.2	6.4	0.2	3.1	12.9	3.4	3.4	3.2	3.6	13.6	3.3	3.4	3.4
Total	\$ 287.4	\$ 313.2	\$ 297.7	\$ 331.1	\$ 1,229.4	\$ 299.8	\$ 323.6	\$ 322.4	\$ 341.9	\$ 1,287.7	\$ 302.2	\$ 319.5	\$ 328.3

